Is India’s diagnostics sector poised for a long-term growth upswing? Axis Securities sees opportunity in three stocks
Dr Lal Pathlabs secured new business.
· LiveMint Markets
Axis Securities sees India’s diagnostics sector entering a multi-year growth upcycle, supported by rising demand, scalable models and strong cash generation.
The analysis
Against that, the stock is +1.9% on the day at ₹1,969.70, and has returned +17.4% over three months. It is trading close to its 52-week high, so expectations were already elevated going in. The pharma & healthcare sector has moved -1.0% over the same period, so Dr Lal Pathlabs is running 18.4 points ahead of its peers.
For Dr Lal Pathlabs, the question is how much of this is already reflected in the price and how much re-rates the pharma & healthcare peer set alongside it.
Market context
- The company directly in focus is LALPATHLAB.
- Sector exposure: Pharma & Healthcare.
In this story
Related coverage
Market wrap: ITC, Apollo Hospital, Dr Reddy's Labs, Bajaj Auto top gainers and losers on Nifty and Sensex on Monday
PVR Inox among 4 stocks hitting 52-week highs; rallied up to 13% in a month
Stock Market Crash LIVE: Sensex Tanks Over 1,200 Points, Nifty 50 Below 22,200; ITC, JSW Steel, IndiGo Among Top Losers
Rs 1 Lakh Became Rs 9 Lakhs in Just 3 Years: How This Multibagger Pharma Stock Delivered Over 700% Return
Buy, Sell Or Hold: HDFC Bank, Vodafone Idea, Poonwalla Fincorp, Emcure Pharma | Ask Profit